Safety, Pharmacokinetics, and Efficacy of Olorinab, a Peripherally Acting, Highly Selective, Full Agonist of the Cannabinoid Receptor 2, in a Phase 2a Study of Patients With Chronic Abdominal Pain Associated With Crohn's Disease.
Crohns Colitis 360
; 3(1): otaa089, 2021 Jan.
Article
in En
| MEDLINE
| ID: mdl-36777064
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Type of study:
Clinical_trials
/
Risk_factors_studies
Language:
En
Journal:
Crohns Colitis 360
Year:
2021
Document type:
Article
Affiliation country:
United States
Country of publication:
United kingdom